Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Photopheresis in HIV-1 Infected Patients Utilizing (Benzoporphyrin Derivative Verteporfin/BPD-MA) and Light.

Zale P. Bernstein, MD, Thomas Dougherty, PhD, Sandra Gollnick, Stanley Schwartz, MD, Supriya Mahajan, James Kepner, Adam Sumlin, Carleton Stewart, Paul Wallace, Harold Walder, Bernard Poiesz, MD

Blood (2007) 110 (11): 2275.

https://doi.org/10.1182/blood.V110.11.2275.2275

Published: 2007

Journal Articles

Co-Expression of CD38 with Zap-70 Is Predictive of Treatment Intervention in Patients (pts) with Early Stage Chronic Lymphocytic Leukemia (CLL).

Jean-Gabriel Coignet, Swaminathan Padmanabhan, MD, Rami Manochakian, MD, Kena C. Miller, NP, Paul Wallace, Ph.D., AnneMarie Block, Ph.D., Asher Alban Chanan-Khan, MD

Blood (2006) 108 (11): 4945.

https://doi.org/10.1182/blood.V108.11.4945.4945

Published: 2006

Journal Articles

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Preliminary Results of a Phase I/II Clinical Trial.

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Patricia Marshall, Swaminathan Padmanabhan, MD, William Brady, Zale P. Bernstein, MD, Paul Wallace, MD, Myron S. Czuczman, MD

Blood (2005) 106 (11): 2974.

https://doi.org/10.1182/blood.V106.11.2974.2974

Published: 2005

Journal Articles

In Vivo Evaluation of Immunomodulating Effects of Lenalidomide (L) on Tumor Cell Microenvironment as a Possible Underlying Mechanism of the Antitumor Effects Observed in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Asher Alban Chanan-Khan, MD, Swaminathan Padmanabhan, MD, Kena C. Miller, NP, Paula Pera, Laurie DiMiceli, Noreen Ersing, Paul Wallace, MD, Michael Rickert, Carl Porter, MD

Blood (2005) 106 (11): 2975.

https://doi.org/10.1182/blood.V106.11.2975.2975

Published: 2005

Journal Articles

Characterization of IMiDs (Immunomodulating Agents) Induced “Flare Reaction” in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels.

Laurie DiMiceli, RN, Kena C. Miller, NP, Michael Rickert, Paul Wallace, MD, Patricia Marshall, Dawn DePaolo, Swaminathan Padmanabhan, MD, Beverly Landrigan, RN, Asher A. Chanan-Khan, MD

Blood (2005) 106 (11): 5049.

https://doi.org/10.1182/blood.V106.11.5049.5049

Published: 2005

Journal Articles

Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Laurie DiMiceli, Swaminathan Padmanabhan, MD, David Lawrence, Zale P. Bernstein, MD, Kenichi Takeshita, MD, David Spaner, Paul Wallace, MD, Catriona Byrne, Cynthia Crystal, Myron S. Czuczman, MD

Blood (2005) 106 (11): 447.

https://doi.org/10.1182/blood.V106.11.447.447

Published: 2005

Journal Articles

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)

Asher Chanan-Khan, Kena C. Miller, Kenichi Takeshita, Alexandra Koryzna, Kathleen Donohue, Zale P. Bernstein, Alice Mohr, Donald Klippenstein, Paul Wallace, Jerome B. Zeldis, Christine Berger, Myron S. Czuczman

Blood (2005) 106 (10): 3348–3352.

https://doi.org/10.1182/blood-2005-02-0669

Published: 2005

NARROW

Photopheresis in HIV-1 Infected Patients Utilizing (Benzoporphyrin Derivative Verteporfin/BPD-MA) and Light.

Co-Expression of CD38 with Zap-70 Is Predictive of Treatment Intervention in Patients (pts) with Early Stage Chronic Lymphocytic Leukemia (CLL).

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Preliminary Results of a Phase I/II Clinical Trial.

In Vivo Evaluation of Immunomodulating Effects of Lenalidomide (L) on Tumor Cell Microenvironment as a Possible Underlying Mechanism of the Antitumor Effects Observed in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Characterization of IMiDs (Immunomodulating Agents) Induced “Flare Reaction” in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels.

Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Photopheresis in HIV-1 Infected Patients Utilizing (Benzoporphyrin Derivative Verteporfin/BPD-MA) and Light.

Co-Expression of CD38 with Zap-70 Is Predictive of Treatment Intervention in Patients (pts) with Early Stage Chronic Lymphocytic Leukemia (CLL).

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Preliminary Results of a Phase I/II Clinical Trial.

In Vivo Evaluation of Immunomodulating Effects of Lenalidomide (L) on Tumor Cell Microenvironment as a Possible Underlying Mechanism of the Antitumor Effects Observed in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Characterization of IMiDs (Immunomodulating Agents) Induced “Flare Reaction” in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels.

Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only